|
Consulting
Statistics for non-Statisticians
Statistical implications of the CGMP’s
Statistical Thinking
Process Capability Studies
- Cp, Cpk
- Tolerance Intervals for natural limits
- Control charts in a GMP environment
- Statistical Process Control / Statistical Quality Control
Process Analytical Technology, PAT
- Three phases of PAT
- True Process Knowledge
Design of Experiments, DoE
- DoE for PAT
- Validation by Design®
- “Quality by Design”
- “Design Space”
- Ruggedness and robustness
- Factorials, fractional factorials
- Plackett-Burman designs
- Response Surface Methodology, RSM
Data Analysis
- Statistical graphics
- Regression and correlation
- Outliers and aberrant values; SOPs
- Significant digits and rounding rules
Bergum’s Method for Content Uniformity
Out-of-Specification Results: FDA OOS Guidance
Trending and Out-of-Trend analysis, OOT
Sampling Plans
- Square Root of (N)+1 plans
- Reviewing sampling SOPs
- ANSI/ASQ Z1.4 attribute plans
- ANSI/ASQ Z1.9 variable plans
- AQL = 0.00 for critical characteristics ?
ICH Q2: Analytical method validation
ICH Q6, Setting specifications; writing SOPs
- X bar ± 3S, friend or foe?
- Distribution analysis of historical data
- Statistical Tolerance Intervals
ICH Q8 Pharmaceutical Development
- DoE for product and process development
ICH Q9 Quality Risk Assessment
Quality Philosophy, TQM, Six Sigma
- Deming, Juran, Ishikawa, Taguchi
USP <1010> Analytical Data
ASTM E11 Statistics and ASTM E55 PAT
|
Upcoming Events |
April/May 2012 - “QbD: Sufficient Statistical Confidence”, Chicagoland Pharmaceutical Discussion Group (CPDG), an AAPS affiliated section, for a dinner meeting (approximately 5:30-8:30 pm).
February 14-15, 2012 - “Mixture Designs For Optimal Formulations (Mix)”, An Introduction to Mixture Designs, Stat-Ease, Minneapolis, MN, http://www.statease.com/clas_mix.html
August 6-10, 2012, - “QbD: Is It about Specification or Sampling Plans?”, 52nd Annual Pharmaceutical Analysis Conference, Devil’s Head Lodge, Merrimac, WI
TBD - “Validation by Design”, An Introduction to Factorial Design of Experiment for Processes, PDA TRI, Washington DC.
TBD - “Pharmaceutical Statistics: Process Validation and Ongoing Monitoring”
|
|
|
|
|
|